Aktie A2PSZF RELMADA THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Relmada Therapeutics, Inc.

Aktien

A2PSZF

US75955J4022

RLMD

Realtime-Estimate Cboe BZX
Andere Börsenplätze
 20:16:46 06.05.2024 		% 5 Tage % 1. Jan.
3,945 USD +7,20 % Intraday Chart für Relmada Therapeutics, Inc. +12,04 % -4,47 %
19.03. Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024
19.03. Relmada Therapeutics, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor
Relmada Therapeutics Provides Corporate Update
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS, Neuro Summit
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology Congress
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from S&P Global BMI Index
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board
Relmada Therapeutics Doses First Person in Phase 3 Trial of REL-1017 for Major Depressive Disorder
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PSZF Aktie
  4. Nachrichten Relmada Therapeutics, Inc.
  5. Andere Sprachen